Entero Therapeutics, Stock Today
| ENTO Stock | 0.51 0 0.39% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Entero Therapeutics, is selling at 0.51200002 as of the 21st of March 2025; that is 0.39% up since the beginning of the trading day. The stock's open price was 0.5121. Entero Therapeutics, has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Entero Therapeutics, symbol was changed from FWBI on 17th of May 2024. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2016 | Category Healthcare | Classification Health Care |
Entero Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 3.25 M outstanding shares of which 139.8 K shares are currently shorted by private and institutional investors with about 0.06 trading days to cover. More on Entero Therapeutics,
Moving together with Entero Stock
Moving against Entero Stock
Entero Stock Highlights
| Older Symbol | FWBI | |||||||||||||||||||||||||||||||||||||||||||||
| Chief President | Jack Syage | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Entero Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Entero Therapeutics,'s financial leverage. It provides some insight into what part of Entero Therapeutics,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Entero Therapeutics, (ENTO) is traded on NASDAQ Exchange in USA. It is located in 777 Yamato Road, Boca Raton, FL, United States, 33431 and employs 9 people. Entero Therapeutics, was previously known as FWBI Old and was traded on NASDAQ Exchange under the symbol FWBI. Entero Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.11 M. Entero Therapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.25 M outstanding shares of which 139.8 K shares are currently shorted by private and institutional investors with about 0.06 trading days to cover.
Entero Therapeutics, generates negative cash flow from operations
Check Entero Therapeutics, Probability Of Bankruptcy
Ownership AllocationEntero Therapeutics, shows 7.2 percent of its outstanding shares held by insiders and 5.98 percent owned by other corporate entities.
Check Entero Ownership Details
Entero Therapeutics, Historical Income Statement
Entero Stock Against Markets
Entero Therapeutics, Corporate Management
| Anna Skowron | Chief Officer | Profile | |
| Jennifer SealeyVoyksner | Senior Development | Profile | |
| Sarah CPA | Chief Officer | Profile | |
| Amy ChandlerSkerkis | QA Affairs | Profile | |
| RPh MBA | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.